Press Releases

SAN FRANCISCO --(BUSINESS WIRE)--Nov. 4, 2021-- Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Thiago

Open-label, randomized, controlled real world study will evaluate use of BT-001, a prescription digital therapeutic (“PDT”) designed to treat type 2 diabetes by changing the behaviors that are root causes Mass General Brigham joins the Colorado Prevention Center and Catalyst Health Network to

Trading to commence on Nasdaq on Oct. 29, 2021 , under the ticker symbol BTTX SAN FRANCISCO & NEW YORK --(BUSINESS WIRE)--Oct. 29, 2021-- Better Therapeutics, Inc. , a prescription digital therapeutics (PDT) company delivering cognitive behavioral therapy to address the root causes of

Open-label, real-world study to evaluate the effectiveness of BT-001 in Catalyst’s community-based, clinically integrated, primary care setting SAN FRANCISCO--( BUSINESS WIRE )-- Better Therapeutics, Inc . (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing

NEW YORK and SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ: MCAD, “Mountain Crest II”), a publicly-traded special purpose acquisition company and Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics (PDT) company

SAN FRANCISCO--( BUSINESS WIRE )-- Better Therapeutics, Inc.  (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, has been invited to present at the  Lake Street’s 5th Annual Best

Pivotal trial of BT-001 in type 2 diabetes expected to be fully enrolled in Q4 2021, with primary endpoint readout in Q1 2022; de novo submission to FDA requesting marketing authorization planned following completion of trial  Clinical development of BT-002 and BT-003 in hypertension and

Provides up to $150 million in total financing in combination with proceeds from previously announced SPAC merger and PIPE investment Funds to support advancement of clinical pipeline and commercialization of first prescription digital therapeutic (PDT) for treating type 2 diabetes SAN FRANCISCO--(

Open-label, real-world study will evaluate BT-001’s cognitive behavioral therapy approach to change behaviors at the root cause of type 2 diabetes Study to evaluate the durability of treatment effect and healthcare utilization changes associated with BT-001 in Catalyst’s community-based, clinically

SAN FRANCISCO--( BUSINESS WIRE )-- Better Therapeutics, Inc.  (“Better Therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is participating in the   Canaccord Genuity 41